-
Safety and Tolerability of Starting Aripiprazole Lauroxil With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months Using Paliperidone Palmitate Monthly as an Active Control in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized Controlled Trial. J. Clin. Psychol. (IF 5.3) Pub Date : 2024-02-28 Leslie Citrome, Sergey Yagoda, Ilda Bidollari, Meihua Wang
Background: Aripiprazole lauroxil (AL) 1064 mg every 2 months following initiation using the AL NanoCrystal Dispersion formulation (ALNCD) plus 30-mg oral aripiprazole was efficacious and well tolerated in a 25-week, randomized, double-blind phase 3 trial in adults with acute schizophrenia. This post hoc analysis further characterized the safety of AL 1064 mg administered every 2 months and that of
-
Associations of MSK1 Methylation and Executive Function With Suicidal Ideation in Adolescents With Major Depressive Disorder: A Prospective Cohort Study. J. Clin. Psychol. (IF 5.3) Pub Date : 2024-02-21 Peiwei Xu, Yuanmei Tao, Hang Zhang, Meijiang Jin, Hanmei Xu, Shoukang Zou, Fang Deng, Lijuan Huang, Hong Zhang, Xiaolan Wang, Xiaowei Tang, Yanping Wang, Li Yin, Xueli Sun
Objective: Adolescent suicide is a major public health problem, and risk of suicide is higher among those with major depressive disorder (MDD), which may be linked to alterations in mitogen- and stress-activated kinase 1 (MSK1) and to defects in executive function. Here, we aimed to investigate the potential impacts of executive function and MSK1 methylation on suicidal ideation in adolescents with
-
A Systematic Review of the Clinical Effects of Cannabis and Cannabinoids in Posttraumatic Stress Disorder Symptoms and Symptom Clusters. J. Clin. Psychol. (IF 5.3) Pub Date : 2024-02-14 Justyne D Rodas, Tony P George, Ahmed N Hassan
Objective: Given the high rate of comorbid posttraumatic stress disorder (PTSD) and cannabis use, it is critical that further research be conducted to address the associated benefits and risks of cannabis use in this population. This systematic review evaluated evidence on the effects of cannabis and cannabinoids on PTSD symptoms and PTSD clusters. Data Sources: A systematic search of PubMed, PsycINFO
-
Physical Exercise and Health, 6: Sedentary Time, Independent of Health-Related Physical Activity, as a Risk Factor for Dementia in Older Adults. J. Clin. Psychol. (IF 5.3) Pub Date : 2024-02-07 Chittaranjan Andrade
Sedentary behaviors are leisurely behaviors that occur during waking hours performed while lying down or seated; examples are relaxing, conversing, using a smartphone, watching television, traveling in private or public transport, and thinking or working at a desk. Sedentary behaviors are common in everyday life; the average person spends 9-10 h/d sedentary. Findings from meta-analyses show that higher
-
Effect of Lurasidone on Social Functioning in Schizophrenia: Post Hoc Analysis of the JEWEL Study. J. Clin. Psychol. (IF 5.3) Pub Date : 2024-01-31 Itaru Miura, Fumiya Sano, Reiko Sakaguchi, Keisuke Okamoto, Hidenori Maruyama
Objective: To evaluate the effects of lurasidone on social functioning in schizophrenia over the course of a 6-week, double-blind, placebo-controlled study and a subsequent 12-week open-label extension study. Methods: A total of 478 patients with schizophrenia (per DSM-IV-TR criteria) randomized to either lurasidone 40 mg/d (n = 245) or placebo (n = 233) in the initial 6-week double-blind study (initiated
-
Telehealth Collaborative Care Led by Clinical Pharmacists for People With Psychosis or Bipolar Disorder: A Propensity Weighted Comparison With Usual Psychiatric Care. J. Clin. Psychol. (IF 5.3) Pub Date : 2024-01-29 Esti Iturralde, Lisa Fazzolari, Natalie E Slama, Stacey E Alexeeff, Stacy A Sterling, Sameer Awsare, Maria T Koshy, Macy Shia
Objective: People with psychosis or bipolar disorder (severe and persistent mental illness [SPMI]) are at high risk for poor psychiatric and chronic illness outcomes, which could be ameliorated through improved health care quality. This study assessed whether a telehealth, collaborative care program managed by psychiatric clinical pharmacists (SPMI Population Care) was associated with improved health
-
Physical Exercise and Health, 5: Sedentary Time, Independent of Health-Related Physical Activity, as a Risk Factor for Adverse Physical Health and Mental Health Outcomes. J. Clin. Psychol. (IF 5.3) Pub Date : 2024-01-29 Chittaranjan Andrade
Medical and neuropsychiatric benefits associated with physical exercise and activity are well recognized. It is less well known that time spent in sedentary behaviors, such as television-viewing or sitting at a desk, are associated with adverse health outcomes even after taking into consideration health-related physical activity. Although sedentary behaviors have become common in daily life, people
-
The Clinician's Tardive Inventory (CTI): A New Clinical Tool for Documenting and Rating Tardive Dyskinesia. J. Clin. Psychol. (IF 5.3) Pub Date : 2024-01-24 Richard M Trosch, Cynthia L Comella, Stanley N Caroff, William G Ondo, Alicia C Shillington, Brandon J LaChappelle, Robert A Hauser, Christoph U Correll, Joseph H Friedman
Objective: Current clinician-rated tardive dyskinesia (TD) symptom scales have not addressed the expanding clinical signs and functional impact of TD. The study objective was to develop and test the reliability of a new integrated instrument. Methods: A movement disorder neurologist devised the outline of the rating scale. A Steering Committee (5 neurologists and 2 psychiatrists) provided revisions
-
CYP2D6 Genotyping and Inhibition as Predictors of Adverse Drug Reactions in Depressive Disorders. J. Clin. Psychol. (IF 5.3) Pub Date : 2024-01-17 Amanda Holck, Marie Asp, Henrik Green, Åsa Westrin, Margareta Reis
Objective: The primary aim of this study was to examine the association between the different predicted phenotypes of the polymorphic CYP2D6 gene and the prevalence of adverse drug reactions in patients suffering from depressive disorders. The secondary aim was to investigate if comedication with CYP2D6 inhibitors resulted in more adverse drug reactions due to phenoconversion. Methods: Between January
-
Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study. J. Clin. Psychol. (IF 5.3) Pub Date : 2024-01-15 Rosarelis Torres, Emily L Czeisler, Sean R Chadwick, Stephen M Stahl, Sandra P Smieszek, Changfu Xiao, Christos M Polymeropoulos, Gunther Birznieks, Mihael H Polymeropoulos
Objective: To determine if iloperidone, a second-generation antipsychotic, reduces symptoms of bipolar mania. Methods: This phase 3, randomized, double-blind, placebo-controlled study was conducted in adults with bipolar mania at 27 US and international sites between April 2021 and September 2022. Participants were randomized 1:1 to iloperidone (up to 24 mg/d given twice daily) or placebo for 4 weeks
-
Clinical Outcomes of Intravenous Ketamine Treatment for Depression in the VA Health System. J. Clin. Psychol. (IF 5.3) Pub Date : 2024-01-08 Paul N Pfeiffer, Jamarie Geller, Dara Ganoczy, Jennifer Jagusch, John Carty, Fe Erlita D Festin, William S Gilmer, Brian Martis, Mohini Ranganathan, Ilse R Wiechers, Avinash Hosanagar
Objective/Background: Intravenous (IV) ketamine is effective for reducing symptoms of major depressive disorder in short-term clinical trials; this study characterized clinical outcomes of repeated infusions in routine clinical practice and the frequency and number of infusions used to sustain symptom improvement. Methods: Records of IV ketamine infusions for depression and associated Patient Health
-
Factors Associated With Oral Anticoagulant Use in Patients With Atrial Fibrillation and Mental Disorders. J. Clin. Psychol. (IF 5.3) Pub Date : 2024-01-03 Dina Farran, Matthew Broadbent, Aikaterini Dima, Mark Ashworth, Fiona Gaughran
Objective: This study aims to identify how mental illness severity interacts with oral anticoagulant (OAC) patterns among people with atrial fibrillation (AF). Methods: AF patients with comorbid mental illness (classified using ICD-10) were identified from the South London and Maudsley Biomedical Research Centre Case Register. CHA2DS2-VASc and ORBIT scales were used to calculate stroke and bleeding
-
Novel Quality Control Metric for the Pharmacotherapy of Major Depressive Disorder: Measuring Guideline Concordance and Its Impact on Symptom Severity. J. Clin. Psychol. (IF 5.3) Pub Date : 2024-01-03 Mason T Breitzig, Fan He, Lan Kong, Guodong Liu, Daniel A Waschbusch, Jeff D Yanosky, Erika F H, Duanping Liao
Objective: Studies suggest that people with major depressive disorder (MDD) often receive treatment that is not concordant with practice guidelines. To evaluate this, we (1) developed a guideline concordance algorithm for MDD pharmacotherapy (GCA-8), (2) scored it using clinical data, and (3) compared its explanation of patient-reported symptom severity to a traditional concordance measure. Methods:
-
Magnitude and Correlates of Symptomatic, Global Illness, and Social Functioning Response; Out-of-Home Placement; and Length of Stay in 1,189 Consecutively Hospitalized Children and Adolescents With Mental Disorders. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-12-27 Viktor B Nöhles, Charlotte Jaite, Kerstin Rubarth, Fabiola H Heuer, Katja Bödeker, Laura Golz, Sibylle M Winter, Christoph U Correll
Objective: To identify outcome predictors in hospitalized youth with mental disorders. Methods: This retrospective analysis of systematically recorded clinical parameters in youth hospitalized for psychiatric treatment in 2004-2015 assessed magnitude and correlates of symptom response (SR), global illness response (GIR), social functioning (SF), out-of-home placement (OOHP), and length of stay (LOS)
-
Long-Term Safety and Efficacy of Initial and Repeat Treatment Courses With Zuranolone in Adult Patients With Major Depressive Disorder: Interim Results From the Open-Label, Phase 3 SHORELINE Study. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-12-27 Andrew J Cutler, Gregory W Mattingly, Susan G Kornstein, Scott T Aaronson, Robert Lasser, Hongling Zhang, Nilanjana Rana, Colville Brown, Seth Levin, Catherine Miller, Mona Kotecha, Fiona Forrestal, James Doherty
Objective: Zuranolone is a positive allosteric modulator of both synaptic and extrasynaptic γ-aminobutyric acid (GABA) type A receptors and a neuroactive steroid approved in the United States as an oral, once-daily, 14-day treatment course for adults with postpartum depression and under investigation for adults with major depressive disorder (MDD). Interim results from the open-label, longitudinal
-
The Effectiveness of Metformin in Managing Second Generation Antipsychotic-Induced Weight Gain in Children and Adolescents. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-12-20 Hua Chen, Ning Lyu, Chadi Calarge, Austin De La Cruz, Wenyaw Chan
Objective: This study aimed to assess the effectiveness of metformin for antipsychotic-induced weight gain (AIWG) and determine whether the timing of metformin initiation and premorbid obesity moderated metformin effectiveness in children and adolescents on treatment with second-generation antipsychotics (SGAs). Methods: A cohort of individuals 6 to 17 years of age, from 2016 to 2021, initiating a
-
A Comparison of Depressive Symptom Self-Reported Measures in the Texas Youth Depression and Suicide Research Network (TX-YDSRN). J. Clin. Psychol. (IF 5.3) Pub Date : 2023-12-18 Karabi Nandy, A John Rush, Thomas Carmody, Beth D Kennard, Graham J Emslie, Holli Slater, Taryn L Mayes, Melissa DeFilippis, Cynthia Garza, Eric A Storch, Sarah M Wakefield, Madhukar H Trivedi
Objective: To evaluate psychometrically and provide crosswalks between 3 self-report measures of depressive symptomatology in youth in psychiatric care settings. Ratings included the Patient Health Questionnaire for Adolescents (PHQ-A), a widely used 9-item self-report; the 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16); and the 5-item Very Quick Inventory of Depressive
-
"When Will All of This End?": A 65-Year-Old Man With Amyotrophic Lateral Sclerosis and Psychiatric Distress. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-12-13 Ethan G Lester, Ottavio V Vitolo, Alice Flaherty, Yvan Beaussant, Margaret Cramer, Rebecca Harley, Jonah N Cohen
Patients with amyotrophic lateral sclerosis (ALS) are impacted both physically and psychiatrically during their illness. Emotional distress (ie, anxiety, depression, stress) is common in patients diagnosed with ALS, as prognosis is poor and there are very few effective treatments. The progression of symptoms is unpredictable, and all cases are terminal. Neuropsychiatric symptoms are also increasingly
-
Physical Exercise and Health, 4: The Health Care Professional and Patient's Guide to Understanding What to Do, How, and Why-Part 2. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-12-11 Chittaranjan Andrade
This article is the fourth in a series on physical exercise and health. The article addresses health care professionals, patients, and the public and provides practical guidance on how to exercise with emphasis on understanding what to do, how, and why. Subjects covered include how cardiorespiratory, muscle-strengthening, load-bearing, balancing, and other exercises benefit the heart, strengthen muscles
-
Social Media Images Can Predict Suicide Risk Using Interpretable Large Language-Vision Models. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-11-29 Yael Badian, Yaakov Ophir, Refael Tikochinski, Nitay Calderon, Anat Brunstein Klomek, Eyal Fruchter, Roi Reichart
Background: Suicide, a leading cause of death and a major public health concern, became an even more pressing matter since the emergence of social media two decades ago and, more recently, following the hardships that characterized the COVID-19 crisis. Contemporary studies therefore aim to predict signs of suicide risk from social media using highly advanced artificial intelligence (AI) methods. Indeed
-
Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-11-27 Jesse R Richards, Madisen Fae Dorand, Kyleigh Royal, Lana Mnajjed, Maria Paszkowiak, W Kyle Simmons
Objective: Despite being a major cause of preventable death worldwide, alcohol use disorder (AUD) currently has only 3 FDA-approved pharmacotherapies. The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide has shown promise in preclinical studies for reducing alcohol consumption, but there are currently no randomized clinical trials that associate a decline in AUD symptoms with semaglutide
-
Acceptance and Mindfulness-Based Exposure Therapy for PTSD After Cardiac Arrest: An Open Feasibility Trial. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-11-22 Maja Bergman, John C Markowitz, Ian M Kronish, Sachin Agarwal, Chana T Fisch, Elizabeth Eder-Moreau, Yuval Neria
Background: Posttraumatic stress disorder (PTSD) is prevalent after surviving sudden cardiac arrest (SCA). SCA-induced PTSD is associated with increased mortality and cardiovascular risk, yet no psychotherapeutic treatment has been developed and tested for this population. Exposure therapy is standard treatment for PTSD, but its safety and efficacy remain unconfirmed for SCA survivors: current protocols
-
Telemental Health Utilization in Commercial Health Insurance Plans in the United States From 2010 Through 2019. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-11-20 Aziza Arifkhanova, Andrew Elhabr, Christian Murray, Jaya Khushalani, Antonio Neri, Jennifer Kaminski PhD, Richard W Puddy, Turgay Ayer
Objective: We sought to characterize patterns of utilization of telemental health among commercially insured individuals over the decade preceding COVID-19. Methods: We developed telemental health service groups from the US PharMetrics Plus database, using diagnostic codes to identify those diagnosed with mental health conditions and procedure codes to capture mental health visits delivered via telehealth
-
Machine Learning Prediction of Quality of Life Improvement During Antidepressant Treatment of Patients With Major Depressive Disorder: A STAR*D and CAN-BIND-1 Report. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-11-15 Tejas Phaterpekar,John-Jose Nunez,Emma Morton,Yang S Liu,Bo Cao,Benicio N Frey,Roumen V Milev,Daniel J Müller,Susan Rotzinger,Claudio N Soares,Valerie H Taylor,Rudolf Uher,Sidney H Kennedy,Raymond W Lam
Background: Quality of life (QoL) is an important patient-centric outcome to evaluate in treatment of major depressive disorder (MDD). This work sought to investigate the performance of several machine learning methods to predict a return to normative QoL in patients with MDD after antidepressant treatment. Methods: Several binary classification algorithms were trained on data from the first 2 weeks
-
Predictors and Risk Factors of Treatment-Resistant Depression: A Systematic Review. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-11-13 Shane J O'Connor,Nilay Hewitt,Joanna Kuc,Lucinda S Orsini
Objective: To systematically review the literature to identify and categorize the predictors and risk factors for treatment-resistant depression (TRD). Data Sources: Online databases (PubMed, MEDLINE, Embase, and APA PsycNet) and relevant conference sources were searched from inception up to January 24, 2022. The following keywords were used: treatment-resistant depression, depressive disorder, predictors
-
Longitudinal Description and Prediction of Smoking Among Borderline Patients: An 18-Year Follow-Up Study. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-11-08 Marcelo J A A Brañas, Frances R Frankenburg, Christina M Temes, Garrett M Fitzmaurice, Mary C Zanarini
Objective: The objectives of this study were (1) to compare smoking between recovered and non-recovered patients with borderline personality disorder (BPD) over the course of 18 years and (2) to assess baseline predictors of tobacco use in patients with BPD. Methods: A total of 264 borderline patients were interviewed concerning their smoking history beginning at the 6-year follow-up wave in a longitudinal
-
Pimavanserin 34 mg at Bedtime for the Treatment of Insomnia in 6 Veterans With Posttraumatic Stress Disorder. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-11-06 Melissa B Jones,Ritwick Agrawal,Amir Sharafkhaneh,Gursimrat Bhatti,Ruosha Li,Laura Marsh,Ricardo E Jorge
-
Medication Adherence in a Transdiagnostic First-Episode Psychosis Sample. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-11-01 Stephanie M London,Philip B Cawkwell,Ann K Shinn
Objective: Medication adherence is an important component of treatment and has the potential to influence illness trajectory in individuals with first-episode psychosis (FEP). We sought to examine time to medication non-adherence as well as factors related to non-adherence in a real-world FEP clinic. Methods: We conducted a survival analysis to examine time to medication non-adherence using data extracted
-
Training for Lasting Change: Trauma-Informed Training Results in Improved and Sustained Individual and Organizational Knowledge, Attitudes, and Policies. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-10-30 Alexandra R Mangus,E Kate Webb,Miri Bar-Halpern,Caitlin Ravichandran,Kerry J Ressler,Alisha Moreland-Capuia
Objective: Trauma-informed care (TIC) trainings seek to improve individual and organizational recognition and care to individuals who have experienced trauma. However, whether TIC trainings result in long-term changes to an organization's policies and practices remains unclear. This article describes the effectiveness of a workshop designed to train professionals across disciplines in understanding
-
Resolving the Paradox of Long-Term Benzodiazepine Treatment: Toward Evidence-Based Practice Guidelines. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-10-25 Edward Silberman,Antonio E Nardi,Vladan Starcevic,Richard Balon,Fiammetta Cosci,Giovanni A Fava,Carl Salzman,Richard Shader,Nicoletta Sonino
-
A Randomized Controlled Trial of Community-Delivered Heated Hatha Yoga for Moderate-to-Severe Depression. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-10-23 Maren B Nyer, Lindsey B Hopkins, Megha Nagaswami, Richard Norton, Chris C Streeter, Bettina B Hoeppner, Chloe E C Sorensen, Lisa Uebelacker, Jill Koontz, Simmie Foster, Christina Dording, Naoise Mac Giollabhui, Albert Yeung, Lauren B Fisher, Cristina Cusin, Felipe A Jain, Paola Pedrelli, Grace A Ding, Ashley E Mason, Paolo Cassano, Darshan H Mehta, Christina Sauder, Charles L Raison, Karen K Miller
Objective: To evaluate feasibility, acceptability, and preliminary efficacy of heated yoga to treat moderate-to-severe depression. Design: An 8-week randomized controlled trial (RCT) of heated yoga versus waitlist control was conducted from March 2017 to August 2019. Methods: Participants in the yoga condition were asked to attend heated yoga classes at 2 community heated yoga studios at least twice
-
Adult Outcomes of Children With Reactive Attachment Disorder in a Non-Institutionalized Sample. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-10-18 Hannah K Betcher,Tanner J Bommersbach,Bruno A Perossa,Beth Larrabee,Paul E Croarkin,Magdalena Romanowicz,Jennifer L Vande Voort,Alastair J McKean
Objective: Research on reactive attachment disorder (RAD) has focused on institutionalized samples, and long-term outcomes have not been described. This study examines the natural history of RAD into adulthood in a US community sample. Methods: The electronic medical record of a tertiary care center was reviewed for individuals who received an ICD-9 or ICD-10 diagnosis of RAD between 3-12 years old
-
Obsessive-Compulsive Spectrum Symptoms Are Associated With Functional Impairment in Children and Adolescents With Psychosis Risk Syndrome: The CAPRIS Study. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-10-16 Laura Vergara,Elena de la Serna,Gisela Sugranyes,Olga Puig,Daniel Ilzarbe,Adriana Fortea,Jordina Tor,Daniel Muñoz-Samons,Marta Rodriguez-Pascual,Javier Alvarez-Subiela,Montserrat Dolz,Inmaculada Baeza
Objective: To compare clinical and functional variables among 3 groups of children and adolescents: subjects at clinical high risk for psychosis (CHR-P) who also have obsessive-compulsive symptoms (OCS), CHR-P patients without OCS, and healthy controls (HC). Methods: A total of 128 CHR-P patients and 98 HC between the ages of 10 and 17 years were recruited as part of a multicenter prospective longitudinal
-
Physical Exercise and Health, 2: Benefits Associated With Different Levels and Patterns of Activity. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-10-11 Chittaranjan Andrade
Physical activity and leisure time exercise are associated with well-documented health benefits. Cohort studies and meta-analyses of such studies show that the benefits of physical activity are dose-dependent, arise at even low levels of activity, improve sharply from low to higher levels of activity, peak at very high levels of activity, and plateau thereafter. The benefits are apparent regardless
-
Solriamfetol for Attention-Deficit/Hyperactivity Disorder in Adults: A Double-Blind Placebo-Controlled Pilot Study. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-10-09 Craig B H Surman, Daniel M Walsh, Nora Horick, Maura DiSalvo, Chloe Hutt Vater, Daniel Kaufman
Objective: Some individuals with attention-deficit/hyperactivity disorder (ADHD) may not tolerate or adequately respond to currently available treatments. This study examined whether solriamfetol could have a favorable pattern of effects and tolerability as a treatment for ADHD in adults. Methods: Sixty adults with DSM-5 ADHD participated from August 2021 through January 2023 in a remotely conducted
-
Exploratory Analysis of the Effects of Celecoxib on Cognitive Function in Vortioxetine-Treated Patients With Major Depressive Disorder in the PREDDICT Study: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-10-04 Emma Sampson, Natalie T Mills, Hikaru Hori, Kathrin Schwarte, Christa Hohoff, Oliver Schubert, Scott R Clark, Célia Fourrier, Bernhard T Baune
Objective: Major depressive disorder (MDD) remains difficult to treat, with many patients resistant to existing treatments or experiencing relapse. Cognitive dysfunction is associated with more severe clinical outcomes. Vortioxetine has shown efficacy in remediating depression-associated cognitive impairment. Anti-inflammatory augmentation of antidepressants is a new strategy in treating depression
-
Physical Exercise and Health, 1: An Overview of Terminology, Guidance, Benefits, and Risks. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-10-04 Chittaranjan Andrade
Regular physical activity in any form is important for health; nevertheless, more than a quarter of adults and more than four-fifths of adolescents do not meet recommended thresholds for exercise. This article outlines the magnitude of the global problem. It discusses terms such as physical activity, aerobic exercise, muscle strengthening exercise, weight-bearing exercise, sitting time, and sedentariness
-
Lemborexant and Daridorexant for the Treatment of Insomnia: An Indirect Comparison Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-10-02 Leslie Citrome, Timothy R Juday, Christie Lundwall
Objective: To determine if there are differences in the number needed to treat (NNT), number needed to harm (NNH), and likelihood to be helped or harmed (LHH) between lemborexant and daridorexant and to compare lemborexant with daridorexant indirectly. Methods: Dichotomous efficacy and tolerability outcomes reported for Phase 3 daridorexant trials (conducted May 29, 2018-May 14, 2020) for months 1
-
Dual Orexin Receptor Antagonists and Suicide Risk: Findings From the WHO Spontaneous Reporting Database. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-09-27 Francesco Salvo,Jean-Arthur Micoulaud-Franchi,Laura Palagini,Pierre A Geoffroy
-
Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia: An Integrated Patient-Level Post Hoc Analysis. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-09-25 Oliver J Lopena, Larry D Alphs, Martha Sajatovic, Ibrahim Turkoz, Liping Sun, Karen L Johnston, Jennifer K Sliwa, Dean M Najarian, H Lynn Starr
Objective: To assess the efficacy and safety of paliperidone palmitate (PP) long-acting injectable antipsychotic (LAI) versus oral antipsychotic (OAP) treatment in adult patients diagnosed with schizophrenia (per DSM-IV or DSM-5 criteria) and varying duration of illness (0-3 years and > 3 years). Methods: Patient-level data from the PRIDE, PROSIPAL, and DREaM studies were included in a post hoc analysis
-
Suicide Attempts in Patients With Amyotrophic Lateral Sclerosis: An Analysis of the Korean National Health Insurance Database. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-09-20 C Hyung Keun,Seok-Jin Choi,Ye-Jee Kim,Sung-Min Kim,Yoon-Ho Hong,Jung-Joon Sung
Objective: The knowledge of the common risk factors for suicide attempts may not be simply applicable to patients with amyotrophic lateral sclerosis (ALS). We aimed to identify risk factors associated with suicide attempts in patients with ALS and to determine the annual prevalence and periods of vulnerability associated with attempts. Methods: This nationwide cohort study was performed using the Korean
-
The Use of Dispensary-Obtained Tetrahydrocannabinol as a Treatment for Neuropsychiatric Symptoms of Dementia. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-09-18 Samantha M Sawicki,Cristian Hernandez,Neda Laiteerapong,Erin K Zahradnik
Objective: Neuropsychiatric symptoms (NPS) of dementia represent a large driver of health care costs, caregiver burden, and institutionalization of people with dementia. Management options are limited, and antipsychotics are often used, although they carry a significant side effect profile. One novel option is tetrahydrocannabinol (THC); however, in the US, to obtain THC for patients with dementia
-
Optimizing Mental Health for Women: Recognizing and Treating Mood Disorders Throughout the Lifespan. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-09-18 Kathryn M Abel,Marlene P Freeman
Mood disorders can come and go during the reproductive stages of a woman's life and beyond and can include premenstrual-related mood disorders, depression and other psychiatric disorders during pregnancy, postpartum mood disorders, and depression during menopause, as well as comorbid psychiatric conditions. Women may have regular contact with health care providers at these various stages in their lives
-
Risk of All-Cause and Suicide Death in Patients With Schizophrenia: An Entire-Population Longitudinal Study in Taiwan. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-09-13 Chih-Ming Cheng,Wen-Han Chang,Shih-Jen Tsai,Cheng-Ta Li,Chia-Fen Tsai,Ya-Mei Bai,Wei-Chen Lin,Tung-Ping Su,Tzeng-Ji Chen,Mu-Hong Chen
Background: Schizophrenia increases mortality from all causes and specific causes. Comprehensive research on modifiable risk factors for early mortality from multiple sources is needed. Methods: Taiwan's National Health Insurance Research Database, which contains claims data from a lifetime insurance program for the whole population, provided extensive medical inpatient and outpatient data categorized
-
Prescribing of Z-Drugs With and Without Opioid Coprescribing to Primary Care Patients in a Large Health Care System From 2019-2020. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-09-11 Akhil Anand,Jeremy Weleff,Nicolas R Thompson,Brian S Barnett
Objective: This study aimed to characterize Z-drug prescribing with and without opioid coprescribing pre- and post-COVID-19 lockdown in the primary care clinics of a large health care system. Methods: A retrospective, cross-sectional study was conducted that measured the prevalence of Z-drug prescribing with and without opioids for adults aged ≥ 18 years that were seen in the primary care clinics of
-
Suicide and All-Cause Mortality Within 1 Year After a Suicide Attempt in the VigilanS Cohort. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-09-11 Alice Demesmaeker,Ali Amad,Emmanuel Chazard,Anne-Laure Demarty,Honorine Schlienger,Emma Lehmann,Christophe Debien,Vincent Jardon,Karim Bounebache,Gregoire Rey,Guillaume Vaiva
Objective: Obtaining better knowledge on the outcomes of patients who attempt suicide is crucial for suicide prevention. The aim of our study was to determine the causes of death 1 year after a suicide attempt (SA) in the VigilanS program, mortality rates, and risk factors associated with any cause of death and suicide. Methods: A prospective cohort of 7,406 people who had attempted suicide between
-
Risk-Sensitive Decision-Making and Self-Harm in Youth Bipolar Disorder. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-09-06 Mikaela K Dimick, Alysha A Sultan, Kody G Kennedy, Sakina J Rizvi, Erika E Forbes, Mark Sinyor, Roger S McIntyre, Eric A Youngstrom, Benjamin I Goldstein
Background: Youth with bipolar disorder (BD) are at high risk for suicide and have high rates of self-harm, which includes both suicide attempts and non-suicidal self-injury. Greater risk-taking has been associated with suicide attempts in youth with major depression, although there are no studies examining the relationship between risk-related decision-making and self-harm in youth with BD. We aimed
-
Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg: Secondary Analysis of Outcomes in Adult Patients With Schizophrenia in a Randomized, Open-label, Parallel-Arm, Pivotal Study. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-09-04 Leslie Citrome, Pedro Such, Murat Yildirim, Jessica Madera-McDonough, Clodagh Beckham, Zhen Zhang, Frank Larsen, Matthew Harlin
Objective: Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU 960) is a new long-acting injectable antipsychotic formulation for administration every 2 months. A randomized, open-label, 32-week trial evaluated the safety, tolerability, and pharmacokinetics of Ari 2MRTU 960 in clinically stable adults with schizophrenia or bipolar I disorder (per DSM-5 criteria). This secondary analysis evaluated the
-
Omega-3 Polyunsaturated Fatty Acids for Core Symptoms of Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-08-30 Ting-Hui Liu, Jheng-Yan Wu, Po-Yu Huang, Chih-Cheng Lai, Jane Pei-Chen Chang, Chien-Ho Lin, Kuan-Pin Su
Objective: Previous studies have shown conflicting results for the effectiveness of omega-3 polyunsaturated fatty acids (PUFAs) in improving attention-deficit/hyperactivity disorder (ADHD) symptoms. This inconsistency may be due to differences in dosage, composition, and treatment duration. The current meta-analysis aims to address this inconsistency by improving subtype analyses and focusing on heterogeneity
-
Changes in Metabolic Parameters and Body Weight in Patients With Prediabetes Treated With Adjunctive Brexpiprazole for Major Depressive Disorder: Pooled Analysis of Short- and Long-Term Clinical Studies. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-08-28 John W Newcomer, Stine R Meehan, Dalei Chen, Malaak Brubaker, Catherine Weiss
Objective: Certain atypical antipsychotics, while efficacious as adjunctive treatments in major depressive disorder (MDD), are associated with metabolic adverse effects and weight gain. This analysis determined the effect of adjunctive brexpiprazole on metabolic parameters and body weight in adults with MDD and prediabetes (ie, at risk of developing diabetes) based on pooled data from 3 short-term
-
Alcohol Use Disorder Treatment in Sexually and Gender Diverse Patients: A Retrospective Cohort Study. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-08-28 Michal J McDowell, Dana S King, Sy Gitin, Amitai S Miller, Abigail W Batchelder, Alisa B Busch, Shelly F Greenfield, Haiden A Huskamp, Alex S Keuroghlian
Objective: While sexually and gender diverse (SGD) people have higher odds of alcohol use disorder (AUD) compared to heterosexual and cisgender people, AUD treatment access and use disparities are not well characterized. The purpose of this study is to assess differences in AUD treatment among SGD versus non-SGD populations. Methods: A retrospective cohort study was performed using data from a federally
-
The Impact of Clozapine Delay on Clinical Outcomes in Schizophrenia. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-08-23 Claire Law, Yuen Mei See, Jie Yin Yee, Boon Tat Ng, Charmaine Tang, Jimmy Lee
Background: Clozapine is the drug of choice indicated for treatment-resistant schizophrenia (TRS), but delays in initiation and underutilization might have affected its effectiveness in practice. In this study, we sought to examine the clinical outcomes of patients on clozapine treatment and if a delay in initiation was associated with poorer outcomes. Methods: This study was conducted at a tertiary
-
COVID-19 Delirium and Motoric Subtypes: Opportunities to Improve Outcomes. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-08-21 Randall T Espinoza,Aaron Kaufman
-
Early Onset Delirium During Hospitalization Increases In-Hospital and Postdischarge Mortality in COVID-19 Patients: A Multicenter Prospective Study. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-08-21 Caterina Trevisan, Giulia Grande, Paola Rebora, Alberto Zucchelli, Maria Grazia Valsecchi, Emanuele Focà, Fiona Ecarnot, Alessandra Marengoni, Giuseppe Bellelli
Objective: Delirium is a common feature in COVID-19 patients. Although its association with in-hospital mortality has previously been reported, data concerning postdischarge mortality and delirium subtypes are scarce. We evaluated the association between delirium and its subtypes and both in-hospital and postdischarge mortality. Methods: This multicenter longitudinal clinical-based study was conducted
-
Cariprazine for the Adjunctive Treatment of Major Depressive Disorder in Patients With Inadequate Response to Antidepressant Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-08-16 Robert Riesenberg,Paul P Yeung,Ludmyla Rekeda,Gary S Sachs,Majid Kerolous,Maurizio Fava
Objective: To assess the efficacy of cariprazine, a dopamine D3-preferring D3/D2 and serotonin 5-HT1A receptor partial agonist, as adjunctive treatment for patients with major depressive disorder (MDD) and inadequate response to ongoing antidepressant therapy (ADT). Methods: This randomized, double-blind, placebo-controlled study was conducted from November 2018 to September 2021. Adults with MDD per
-
Nitrous Oxide Reduced Suicidal Ideation in Treatment-Resistant Major Depression in Exploratory Analysis. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-08-16 Victoria C de Leon,Arun Kumar,Peter Nagele,Ben J Palanca,Britt Gott,Alvin Janski,Charles F Zorumski,Charles R Conway
-
Staying Up to Date With Evolving Postpartum Depression Pathophysiology and Treatment Research. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-08-14 Kristina M Deligiannidis,Rubiahna Vaughn
Perinatal depression (PND) is one of the most common medical conditions associated with pregnancy, with 1 in 7 women impacted by PND symptoms and 1 in 13 meeting criteria for major depressive disorder. Unfortunately, half of postpartum depression (PPD) cases begin during pregnancy but are not diagnosed until postpartum. Delayed diagnosis and treatment of PND lead to poor outcomes for both mother and
-
Have Effective Antidepressants Finally Arrived? Developments in Major Depressive Disorder Therapy. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-08-14 Michael E Thase
Among the greatest unmet needs in major depressive disorder (MDD) is a lack of effective pharmacotherapies for patients who do not respond to first- and second-line antidepressant medications. After decades of muted progress, optimism regarding the future of MDD therapy rose after scientists serendipitously uncovered the antidepressant effects of ketamine. The discovery of ketamine's antidepressant
-
The Lifetime Burden of Schizophrenia as Estimated by a Government-Centric Fiscal Analytic Framework. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-08-09 Rui Martins,Aditi Kadakia,G Rhys Williams,Snezana Milanovic,Mark P Connolly
Objective: To estimate the fiscal consequences of schizophrenia compared to the general US population using a "government perspective" fiscal analytic modeling framework capturing lost tax revenue and broader government costs in 2021. Methods: Schizophrenia was modeled from age 23 using a cohort-based Markov chain with 6-week cycles, simulating the effect of antipsychotic treatment sequences on remission
-
Reviewing Non-Dopaminergic Mechanisms for Positive and Negative Schizophrenia Symptom Management. J. Clin. Psychol. (IF 5.3) Pub Date : 2023-08-07 Leslie Citrome,Jonathan M Meyer
Schizophrenia is a chronic and debilitating mental health condition that significantly impacts quality of life and can shorten patients' lifetime by decades. It is characterized by symptoms including hallucinations and delusions, apathy, and cognitive impairment, and people with schizophrenia also experience many somatic comorbidities, such as metabolic disturbances, infectious diseases, cardiovascular